Chronic recurrent multifocal osteomyelitis primarily affecting the spine treated with anti-TNF therapy

• Published in: Spine (Philadelphia, Pa. 1976) Pa. 1976), 2010-04, Vol.35 (7), p.E253-E256
• Main Authors: Marangoni, Roberta G, Halpern, Ari S R
• Format: Article
• Language: English
• Subjects: Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal - therapeutic use; Chronic Disease; Diagnosis, Differential; Discitis - diagnosis; Humans; Infliximab; Male; Osteomyelitis - diagnosis; Osteomyelitis - drug therapy; Osteomyelitis - immunology; Pain; Spinal Diseases - diagnosis; Spinal Diseases - drug therapy; Spinal Diseases - immunology; Treatment Outcome
• ISSN: 0362-2436; 1528-1159
• DOI: 10.1097/BRS.0b013e3181c09601

A case report describing chronic recurrent multifocal osteomyelitis (CRMO) with initial presentation limited to spine, successfully treated by anti-TNF-alpha therapy after failure of conventional treatment methods. To describe an unusual manifestation and treatment of a rare disease. CRMO is a rare inflammatory bone disease that should be differentiated from bacterial osteomyelitis. Rarely, it can affect the spine and in this case the most important differential diagnosis is infectious spondylodiscitis. The disease has an unpredictable course with exacerbations and spontaneous remissions. Although the majority of cases remit spontaneously (or after the use of nonsteroidal anti-inflammatory drugs [NSAIDs]), some progressive and resistant cases have been reported. We describe a case of CRMO with an unusual clinical presentation emphasizing the importance of this finding as a differential diagnosis of spondylodiscitis and comment on the available treatment alternatives. A 17-year-old man presented with debilitating dorsal spine pain. Magnetic resonance imaging of the spine revealed bone lesions at multiple vertebral levels. After failure of antibiotic treatment, the diagnosis of CRMO was suggested. An initial good response to NSAIDs was followed by a recurrent course and involvement of peripheral joints besides the use of corticosteroids and other drugs. The introduction of infliximab was followed by complete remission of the disease. Our observation highlights the need of awareness for the differential diagnosis in suspected cases of osteomyelitis not responding to antibiotics. Anti-TNF-alpha agents should be considered in CRMO refractory cases.